METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastoma.
Journal
Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011
Informations de publication
Date de publication:
21 Mar 2024
21 Mar 2024
Historique:
accepted:
18
12
2023
revised:
08
12
2023
received:
06
12
2022
pubmed:
5
1
2024
medline:
5
1
2024
entrez:
5
1
2024
Statut:
ppublish
Résumé
Telomerase-negative tumors maintain telomere length by alternative lengthening of telomeres (ALT), but the underlying mechanism behind ALT remains poorly understood. A proportion of aggressive neuroblastoma (NB), particularly relapsed tumors, are positive for ALT (ALT+), suggesting that a better dissection of the ALT mechanism could lead to novel therapeutic opportunities. TERRA, a long non-coding RNA (lncRNA) derived from telomere ends, localizes to telomeres in a R-loop-dependent manner and plays a crucial role in telomere maintenance. Here we present evidence that RNA modification at the N6 position of internal adenosine (m6A) in TERRA by the methyltransferase METTL3 is essential for telomere maintenance in ALT+ cells, and the loss of TERRA m6A/METTL3 results in telomere damage. We observed that m6A modification is abundant in R-loop enriched TERRA, and the m6A-mediated recruitment of hnRNPA2B1 to TERRA is critical for R-loop formation. Our findings suggest that m6A drives telomere targeting of TERRA via R-loops, and this m6A-mediated R-loop formation could be a widespread mechanism employed by other chromatin-interacting lncRNAs. Furthermore, treatment of ALT+ NB cells with a METTL3 inhibitor resulted in compromised telomere targeting of TERRA and accumulation of DNA damage at telomeres, indicating that METTL3 inhibition may represent a therapeutic approach for ALT+ NB.
Identifiants
pubmed: 38180812
pii: 7511755
doi: 10.1093/nar/gkad1242
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2648-2671Subventions
Organisme : Swedish Research Council
ID : 2018-02224
Organisme : Cancerfonden
ID : 22-2341
Organisme : Barncancerfonden
ID : PR 2019-077
Organisme : Svenska Läkaresällskapet
Organisme : Åke Wibergs Stiftelse
Organisme : Kungl Vetenskaps- och Vitterhets-Samhället
Organisme : Barncancerfonden
ID : TJ 2019-0077
Organisme : Cancerfonden
ID : 23-0753 PT
Organisme : Tore Nilsons Stiftelse and Bollan scholarship
Organisme : Assar Gabrielsson Fond
Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.